Javier Cortés, MD, PhD: Clinical Insights on Using Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

Posted: Tuesday, September 28, 2021

Javier Cortés, MD, PhD, of Barcelona’s IOB Institute of Oncology, offers key insights into the findings of the DESTINY-Breast03 study on trastuzumab deruxtecan as a possible new standard of care for metastatic HER2-positive breast cancer, the safety profile of this agent compared with trastuzumab emtansine, and the clinical implications of treatment moving forward.